LABP Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Landos Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.93 |
| 52 Week High | US$22.94 |
| 52 Week Low | US$2.50 |
| Beta | 0.14 |
| 11 Month Change | 2.78% |
| 3 Month Change | 267.47% |
| 1 Year Change | 693.43% |
| 33 Year Change | -79.12% |
| 5 Year Change | n/a |
| Change since IPO | -80.89% |
Recent News & Updates
Recent updates
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
Mar 22
Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer
Sep 06Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky
Aug 19Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
May 05Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business
Nov 17Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting
Jun 14Landos Biopharma (LABP) Investor Presentation - Slideshow
Jun 08We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully
May 04Shareholder Returns
| LABP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.0% | -0.8% | 1.8% |
| 1Y | 693.4% | 22.3% | 31.9% |
Return vs Industry: LABP exceeded the US Pharmaceuticals industry which returned 18.6% over the past year.
Return vs Market: LABP exceeded the US Market which returned 25.6% over the past year.
Price Volatility
| LABP volatility | |
|---|---|
| LABP Average Weekly Movement | 49.2% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LABP's share price has been volatile over the past 3 months.
Volatility Over Time: LABP's weekly volatility has increased from 26% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 19 | Greg Oakes | landosbiopharma.com |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company’s preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD.
Landos Biopharma, Inc. Fundamentals Summary
| LABP fundamental statistics | |
|---|---|
| Market cap | US$71.68m |
| Earnings (TTM) | -US$24.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs LABP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.80m |
| Earnings | -US$24.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LABP perform over the long term?
See historical performance and comparison